References
- van de Vooren K, Curto A, Garattini L. Biosimilar versus generic drugs: same but different? Appl Health Econ Health Policy. 2015;13:125–127.
- European Medicines Agency. Questions and answers on generic medicines. 22 Nov 2012. EMA/393905/2006 Rev 2. [cited 2014 Dec 9]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500012382.pdf
- European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). 27 Sep 2012. EMA/837805/2011. [cited 2014 Dec 9]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf.
- Crommelin DJA, de Vlieger JSB, Eds. Non-biological complex drugs. The science and the regulatory landscape. 1st ed. NY: AAPS/Springer, Advances in the Pharmaceutical Sciences Series; 2015.
- Crommelin DJ, de Vlieger JS, Weinstein V, et al. Different pharmaceutical products need similar terminology. Aaps J. 2014;16(1):11–14.
- Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, as amended. [cited 9 Dec 2014]. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_83_ cons2009/2001_83_cons2009_en.pdf.
- European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the investigation of bioequivalence. 20 Jan 2010. CPMP/EWP/QWP/1401/98. [cited 2014 Dec 14]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf.
- Vogel AM. Hybrid or mixed marketing authorization application in the European Union: not a trivial decision in new development programs for established drugs. Drug Inf J. 2012. DOI:10.1177/0092861512443748
- European Medicines Agency. [cited 2014 Dec 9]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp#Product-specific biosimilar guidelines.
- Crommelin DJ, Shah VP, Klebovich I, et al. The similarity question for biological and non-biological complex drugs. Eur J Pharm Sci. 2015;76:10–17.
- European Medicine Agency 2009 EMA/CHMP/806058/2009/Rev, 2013. Committee for Human Medicinal Products (CHMP) Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal products. London: EMA.
- European Medicine Agency, 2013. Committee for Medicinal Products for Human Use (CHMP). Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product EMA/CHMP/SWP/620008/2012. London: EMA.
- Ehmann F, Pita R. The EU is ready for non-biological complex medicinal products. Gabi J. 2016;5(1):30–35.
- Barei F, Ross M. The refinement of the super generic concept: semantic challenge for product re-innovation? Gabi J. 2015;4(1):25–32.
- Lakemedelsverket. Decision concerning the substitutability group glatiramer injection solution, prefilled syringe 20 mg/ml. Stockholm (Sweden): Lakemedelsverket; 2016 July 8.